593 related articles for article (PubMed ID: 25800968)
1. Switching haemophilia products and inhibitor risk: a United States' perspective.
Nance D; Rodgers GM
Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
[No Abstract] [Full Text] [Related]
2. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
[No Abstract] [Full Text] [Related]
3. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.
Shirahata A; Fukutake K; Higasa S; Mimaya J; Oka T; Shima M; Takamatsu J; Taki M; Taneichi M; Yoshioka A;
Haemophilia; 2011 Sep; 17(5):771-6. PubMed ID: 21682824
[TBL] [Abstract][Full Text] [Related]
4. The management of hemophilia patients with inhibitors.
Nilsson IM
Transfus Med Rev; 1992 Oct; 6(4):285-93. PubMed ID: 1421831
[No Abstract] [Full Text] [Related]
5. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
Hedner U
Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
[No Abstract] [Full Text] [Related]
6. Key issues in inhibitor management in patients with haemophilia.
Gomez K; Klamroth R; Mahlangu J; Mancuso ME; Mingot ME; Ozelo MC
Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s319-29. PubMed ID: 24333092
[No Abstract] [Full Text] [Related]
7. Inhibitor eradication with rituximab in haemophilia: where do we stand?
Franchini M; Mannucci PM
Br J Haematol; 2014 Jun; 165(5):600-8. PubMed ID: 24628543
[TBL] [Abstract][Full Text] [Related]
8. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
[TBL] [Abstract][Full Text] [Related]
9. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
Nilsson IM; Berntorp E
Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694
[No Abstract] [Full Text] [Related]
10. Recombinant clotting factors in the treatment of hemophilia.
Lee C
Thromb Haemost; 1999 Aug; 82(2):516-24. PubMed ID: 10605745
[No Abstract] [Full Text] [Related]
11. How to manage invasive procedures in children with haemophilia.
Ljung RC; Knobe K
Br J Haematol; 2012 Jun; 157(5):519-28. PubMed ID: 22390160
[TBL] [Abstract][Full Text] [Related]
12. A therapeutic alternative for haemophiliacs with inhibitors.
Schulman S
Acta Paediatr; 1992; 81(6-7):564-5. PubMed ID: 1392376
[No Abstract] [Full Text] [Related]
13. Inhibitors - cellular aspects and novel approaches for tolerance.
Scott DW
Haemophilia; 2014 May; 20 Suppl 4(0 4):80-6. PubMed ID: 24762281
[TBL] [Abstract][Full Text] [Related]
14. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.
Astermark J; Morado M; Rocino A; van den Berg HM; von Depka M; Gringeri A; Mantovani L; Garrido RP; Schiavoni M; Villar A; Windyga J;
Haemophilia; 2006 Jul; 12(4):363-71. PubMed ID: 16834735
[TBL] [Abstract][Full Text] [Related]
15. Second-generation recombinant factor VIII and inhibitor risk: interpretation of RODIN study findings and implications for patients with haemophilia A.
van der Bom JG; Gouw SC; Rosendaal FR
Haemophilia; 2014 Mar; 20(2):e171-4. PubMed ID: 24372628
[No Abstract] [Full Text] [Related]
16. Surgery in haemophilic patients with inhibitors.
Rodriguez-Merchan EC
Haemophilia; 2004 Sep; 10 Suppl 2():1-2. PubMed ID: 15385039
[No Abstract] [Full Text] [Related]
17. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
Schimpf K; Schwarz P; Kunschak M
Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
[No Abstract] [Full Text] [Related]
18. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors.
DiMichele DM; Kroner BL;
Thromb Haemost; 2002 Jan; 87(1):52-7. PubMed ID: 11848456
[TBL] [Abstract][Full Text] [Related]
19. Overview of inhibitors.
Astermark J
Semin Hematol; 2006 Apr; 43(2 Suppl 4):S3-7. PubMed ID: 16690373
[TBL] [Abstract][Full Text] [Related]
20. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
